Literature DB >> 24683224

The effect of sumatriptan on nitric oxide synthase enzyme production after iatrogenic inflammation in the brain stem of adolescent rats: A randomized, controlled, experimental study.

Savas Demirpence1, Semra Hiz Kurul1, Müge Kiray2, Kazim Tugyan2, Osman Yilmaz3, Galip Köse1.   

Abstract

BACKGROUND: Migraine is a common disabling disorder of childhood and adolescence. Despite advances in the understanding of migraine pathophysiology, treatment remains a challenge.
OBJECTIVES: The aims of this study were to investigate the production of nitric oxide synthase (NOS) enzymes in the brain stem of adolescent rats, using an experimental model of migraine, and the effect of sumatriptan pretreatment on the production of the NOS enzymes.
METHODS: Male adolescent (aged ~2 months) Wistar rats were used in the study. The animals were anesthetized using pentobarbital. The trigeminovascular system was stimulated by injecting a proinflammatory molecule, carrageenan, into the cis-terna magna of the anesthetized rats. The animals were divided into 3 groups of equal size: (1) the study group, in which the rats were treated with sumatriptan succinate 2 hours before intracisternal carrageenan injection; (2) the sham group, in which the rats were not administered intracisternal carrageenan injection or sumatriptan pretreatment; and (3) the control group, in which the rats were administered intracisternal carrageenan injection but were not pretreated with sumatriptan. In the control and study groups, the rats were euthanized using ether anesthesia 1 hour after intracisternal carrageenan injection. Rats in the sham group were euthanized 1 hour after intracisternal catheterization. Brain tissue was removed and endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS) immunohistochemistry was performed.
RESULTS: Twenty-one rats were randomized into 3 groups of 7. The mean values of the immunolabeling intensities for eNOS, nNOS, and iNOS enzymes in the brain stem were significantly lower in the sham group compared with the control group (P = 0.001, P = 0.002, and P = 0.001, respectively). The mean values of the immunolabeling intensities of eNOS, nNOS, and iNOS in the brain stem were significantly lower in the study group compared with the control group (P = 0.001, P = 0.025, and P = 0.005, respectively).
CONCLUSIONS: In this experimental model of migraine in adolescent rats, intracisternal injection of carrageenan was associated with a significant increase in the production of NOS enzymes in the brain stem. Pretreatment with sumatriptan was associated with a decrease in NOS production.

Entities:  

Keywords:  adolescence; carrageenan; migraine; nitric oxide synthase; sumatriptan

Year:  2009        PMID: 24683224      PMCID: PMC3967298          DOI: 10.1016/j.curtheres.2009.04.003

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  17 in total

1.  Increased expression of endothelial and neuronal nitric oxide synthase in dura and pia mater after air stress.

Authors:  T Zinck; R Illum; I Jansen-Olesen
Journal:  Cephalalgia       Date:  2006-01       Impact factor: 6.292

Review 2.  New and future migraine therapy.

Authors:  Nabih M Ramadan; Thomas M Buchanan
Journal:  Pharmacol Ther       Date:  2006-06-23       Impact factor: 12.310

3.  Immunohistochemical localization of endothelial isoform (eNOS) in human cerebral arteries and the aorta.

Authors:  Yong Liang; Marong Fang; Jicheng Li; David T Yew
Journal:  Int J Neurosci       Date:  2006-12       Impact factor: 2.292

4.  Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain.

Authors:  Lidija Bach-Rojecky; Zdravko Lacković
Journal:  Croat Med J       Date:  2005-04       Impact factor: 1.351

5.  Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics.

Authors:  Helle K Iversen; Jes Olesen; Peer Tfelt-Hansen
Journal:  Pain       Date:  1989-07       Impact factor: 6.961

6.  Increase in meningeal blood flow by nitric oxide--interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition.

Authors:  T Strecker; M Dux; K Messlinger
Journal:  Cephalalgia       Date:  2002-04       Impact factor: 6.292

Review 7.  Animal models of migraine: looking at the component parts of a complex disorder.

Authors:  A Bergerot; P R Holland; S Akerman; T Bartsch; A H Ahn; A MaassenVanDenBrink; U Reuter; C Tassorelli; J Schoenen; D D Mitsikostas; A M J M van den Maagdenberg; P J Goadsby
Journal:  Eur J Neurosci       Date:  2006-09       Impact factor: 3.386

Review 8.  Triptans for treatment of acute pediatric migraine: a systematic literature review.

Authors:  Paul W Major; Helen S I Grubisa; Norman M R Thie
Journal:  Pediatr Neurol       Date:  2003-11       Impact factor: 3.372

9.  CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges.

Authors:  K Nozaki; M A Moskowitz; P Boccalini
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

10.  Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow.

Authors:  Thomas Strecker; Mária Dux; Karl Messlinger
Journal:  J Vasc Res       Date:  2002 Nov-Dec       Impact factor: 1.934

View more
  2 in total

1.  Spontaneous trigeminal allodynia in rats: a model of primary headache.

Authors:  Michael L Oshinsky; Menka M Sanghvi; Christina R Maxwell; Dorian Gonzalez; Rebecca J Spangenberg; Marnie Cooper; Stephen D Silberstein
Journal:  Headache       Date:  2012-09-10       Impact factor: 5.887

2.  Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid.

Authors:  Eleonóra Spekker; Klaudia Flóra Laborc; Zsuzsanna Bohár; Gábor Nagy-Grócz; Annamária Fejes-Szabó; Mónika Szűcs; László Vécsei; Árpád Párdutz
Journal:  J Headache Pain       Date:  2021-03-31       Impact factor: 7.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.